Joyce Cheung-Flynn

Prof. Dr. Joyce Cheung-Flynn


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in JAMA Surgery
Verified
Journal Article
Closed access
FLFan Dong Li
Fan Dong Li
SESusan Eagle
Susan Eagle
CBColleen Brophy
Colleen Brophy
KHKyle M. Hocking
Kyle M. Hocking
MOMichael Osgood
Michael Osgood
JCJoyce Cheung-Flynn
Joyce Cheung-Flynn
Long-term patency of human saphenous veins (HSVs) used as autologous conduits for coronary artery bypass grafting (CABG) procedures remains limited because of vein graft failure (VGF). Vein graft failure has been reported to be as high as 45% at 12 to 18 months after surgery and leads to additional surgery, myocardial infarction, recurrent angina, and death. Preparation of HSVs before implantation leads to conduit injury, which may promote VGF. To investigate whether pressure distension during vein graft preparation leads to endothelial injury and intimal thickening and whether limiting intraluminal pressure during pressure distension by using a pressure release valve (PRV) preserves endothelial function and prevents neointima thickening. Segments of HSVs were collected in a university hospital from 13 patients undergoing CABG procedures immediately after harvest (unmanipulated [UM]), after pressure distension (after distension [AD]), and after typical intraoperative surgical graft preparation (after manipulation [AM]). Porcine saphenous veins (PSVs) from 7 healthy research animals were subjected to manual pressure distension with or without an in-line PRV that prevents pressures of 140 mm Hg or greater. Endothelial function of the HSVs and PSVs was determined in a muscle bath, endothelial integrity was assessed, and intimal thickening in PSVs was evaluated after 14 days in organ culture. Endothelial function was measured in force, converted to stress, and defined as the percentage relaxation of maximal phenylephrine-induced contraction. Endothelial integrity was assessed by immunohistologic examination. Neointimal thickness was measured by histomorphometric analysis. Pressure distension of HSVs led to decreased mean (SEM) endothelial-dependent relaxation (5.3% [2.3%] for AD patients vs 13.7% [2.5%] for UM patients; P < .05) and denudation. In the AM group, the function of the conduits was further decreased (-3.2% [3.2%]; P < .05). Distension of the PSVs led to reduced endothelial-dependent relaxation (7.6% [4.4%] vs 61.9% [10.2%] in the control group; P < .05), denudation, and enhanced intimal thickening (15.0 [1.4] µm vs 2.2 [0.8] µm in the control group; P < .05). Distension with the PRV preserved endothelial-dependent relaxation (50.3% [9.6%]; P = .32 vs control), prevented denudation, and reduced intimal thickening (3.4 [0.8] µm; P = .56 vs controls) in PSVs. Use of a PRV during graft preparation limits intraluminal pressure generated by manual distension, preserves endothelial integrity, and reduces intimal hyperplasia. Integration of this simple device may contribute to improved long-term vein graft patency.

8 October 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
JTJ. William Tierney
J. William Tierney
BEBrian C. Evans
Brian C. Evans
JCJoyce Cheung-Flynn
Joyce Cheung-Flynn
BWBo Wang
Bo Wang
JCJuan M. Colazo
Juan M. Colazo
CDCraig Duvall
Craig Duvall
Vascular procedures, such as stenting, angioplasty, and bypass grafting, often fail due to intimal hyperplasia (IH), wherein contractile vascular smooth muscle cells (VSMCs) dedifferentiate to synthetic VSMCs, which are highly proliferative, migratory, and fibrotic. Previous studies suggest MAPK-activated protein kinase 2 (MK2) inhibition may limit VSMC proliferation and IH, although the molecular mechanism underlying the observation remains unclear. We demonstrated here that MK2 inhibition blocked the molecular program of contractile to synthetic dedifferentiation and mitigated IH development. Molecular markers of the VSMC contractile phenotype were sustained over time in culture in rat primary VSMCs treated with potent, long-lasting MK2 inhibitory peptide nanopolyplexes (MK2i-NPs), a result supported in human saphenous vein specimens cultured ex vivo. RNA-Seq of MK2i-NP–treated primary human VSMCs revealed programmatic switching toward a contractile VSMC gene expression profile, increasing expression of antiinflammatory and contractile-associated genes while lowering expression of proinflammatory, promigratory, and synthetic phenotype–associated genes. Finally, these results were confirmed using an in vivo rabbit vein graft model where brief, intraoperative treatment with MK2i-NPs decreased IH and synthetic phenotype markers while preserving contractile proteins. These results support further development of MK2i-NPs as a therapy for blocking VSMC phenotype switch and IH associated with cardiovascular procedures.

20 February 2015 in Journal of Vascular Surgery
Verified
Journal Article
Open access
PDF file
KHKyle M. Hocking
Kyle M. Hocking
WLWeifeng Luo
Weifeng Luo
FLFan Dong Li
Fan Dong Li
PKPadmini Komalavilas
Padmini Komalavilas
CBColleen Brophy
Colleen Brophy
JCJoyce Cheung-Flynn
Joyce Cheung-Flynn
Background Injury to saphenous vein grafts during surgical preparation may contribute to the subsequent development of intimal hyperplasia, the primary cause of graft failure. Surgical skin markers currently used for vascular marking contain gentian violet and isopropanol, which damage tissue and impair physiologic functions. Brilliant blue FCF (FCF) is a nontoxic dye alternative that may also ameliorate preparation-induced injury. Methods Porcine saphenous vein (PSV) was used to evaluate the effect of FCF on physiologic responses in a muscle bath. Cytotoxicity of FCF was measured using human umbilical venous smooth muscle cells. Effect of FCF on the development of intimal hyperplasia was evaluated in organ culture using PSV. Intracellular calcium fluxes and contractile responses were measured in response to agonists and inhibitors in rat aorta and human saphenous vein. Results Marking with FCF did not impair smooth muscle contractile responses and restored stretch injury-induced loss in smooth muscle contractility of PSV. Gentian violet has cytotoxic effects on human umbilical venous smooth muscle cells, whereas FCF is nontoxic. FCF inhibited intimal thickening in PSV in organ culture. Contraction induced by 2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate and intracellular calcium flux were inhibited by FCF, oxidized adenosine triphosphate, KN-62, and brilliant blue G, suggesting that FCF may inhibit the purinergic receptor P2X7. Conclusions Our studies indicated that FCF is a nontoxic marking dye for vein grafts that ameliorates vein graft injury and prevents intimal thickening, possibly due to P2X7 receptor inhibition. FCF represents a nontoxic alternative for vein graft marking and a potentially therapeutic approach to enhance outcome in autologous transplantation of human saphenous vein into the coronary and peripheral arterial circulation.

1 November 2014 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
IVIgor V. Voskresensky
Igor V. Voskresensky
EWEric S. Wise
Eric S. Wise
KHKyle M. Hocking
Kyle M. Hocking
FLFan Dong Li
Fan Dong Li
MOMichael J. Osgood
Michael J. Osgood
JCJoyce Cheung-Flynn
Joyce Cheung-Flynn
The leading cause of failure of saphenous vein grafts used in arterial bypass procedures is intimal hyperplasia.1 While incompletely understood, intimal hyperplasia results from a cascade of molecular and cellular events that are triggered by injury. This process leads to pathologic narrowing of the vessel lumen, graft stenosis, and ultimately graft failure.2 Despite the many recent technological advances in cardiovascular interventions, intimal hyperplasia remains an expensive, morbid, and unsolved problem.

13 September 2017 in Purinergic Signalling
Verified
Journal Article
Closed access
PDF file
WLWeifeng Luo
Weifeng Luo
DFDaniel Feldman
Daniel Feldman
RMReid McCallister
Reid McCallister
CBColleen Brophy
Colleen Brophy
JCJoyce Cheung-Flynn
Joyce Cheung-Flynn

1 July 2018 in Journal of Controlled Release
Verified
Journal Article
Closed access
AMAlvin J. Mukalel
Alvin J. Mukalel
BEBrian C. Evans
Brian C. Evans
KKKameron V. Kilchrist
Kameron V. Kilchrist
EDEric A. Dailing
Eric A. Dailing
BBBenjamin Burdette
Benjamin Burdette
CDCraig Duvall
Craig Duvall